175 related articles for article (PubMed ID: 27302598)
1. Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs.
Panteri A; Kukk A; Desevaux C; Seewald W; King JN
J Vet Pharmacol Ther; 2017 Jan; 40(1):44-56. PubMed ID: 27302598
[TBL] [Abstract][Full Text] [Related]
2. Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats.
King JN; Panteri A; Graille M; Seewald W; Friton G; Desevaux C
BMC Vet Res; 2016 Jun; 12(1):124. PubMed ID: 27338786
[TBL] [Abstract][Full Text] [Related]
3. Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney.
Pelligand L; Suemanotham N; King JN; Seewald W; Syme H; Smith K; Lees P; Elliott J
BMC Vet Res; 2015 Dec; 11():296. PubMed ID: 26634699
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.
Lantis AC; Ames MK; Atkins CE; DeFrancesco TC; Keene BW; Werre SR
J Vet Pharmacol Ther; 2015 Feb; 38(1):65-73. PubMed ID: 25224804
[TBL] [Abstract][Full Text] [Related]
5. Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.
Fusellier M; Desfontis JC; Madec S; Gautier F; Marescaux L; Debailleul M; Gogny M
J Vet Pharmacol Ther; 2005 Dec; 28(6):581-6. PubMed ID: 16343292
[TBL] [Abstract][Full Text] [Related]
6. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2.
King JN; Arnaud JP; Goldenthal EI; Gruet P; Jung M; Seewald W; Lees P
J Vet Pharmacol Ther; 2011 Jun; 34(3):298-311. PubMed ID: 21492194
[TBL] [Abstract][Full Text] [Related]
7. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.
Ames MK; Atkins CE; Lee S; Lantis AC; zumBrunnen JR
Am J Vet Res; 2015 Dec; 76(12):1041-50. PubMed ID: 26618728
[TBL] [Abstract][Full Text] [Related]
8. Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs.
Adin D; Atkins C; Wallace G; Klein A
J Vet Intern Med; 2021 May; 35(3):1245-1254. PubMed ID: 33713485
[TBL] [Abstract][Full Text] [Related]
9. Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs.
Toutain CE; Heit MC; King SB; Helbig R
BMC Vet Res; 2017 Nov; 13(1):359. PubMed ID: 29179750
[TBL] [Abstract][Full Text] [Related]
10. Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.
Toutain CE; Brossard P; King SB; Helbig R
BMC Vet Res; 2018 Aug; 14(1):242. PubMed ID: 30119677
[TBL] [Abstract][Full Text] [Related]
11. Renal actions of the new angiotensin-converting enzyme inhibitor benazepril hydrochloride.
Levens NR
Arch Int Pharmacodyn Ther; 1988; 296():131-43. PubMed ID: 2853611
[TBL] [Abstract][Full Text] [Related]
12. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs.
Friton G; Thompson CM; Karadzovska D; King S; King JN
BMC Vet Res; 2017 Jun; 13(1):197. PubMed ID: 28651573
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M
Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774
[TBL] [Abstract][Full Text] [Related]
15. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
Lantis AC; Ames MK; Werre S; Atkins CE
J Vet Pharmacol Ther; 2015 Oct; 38(5):513-7. PubMed ID: 25771846
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Injectable Robenacoxib for the Treatment of Pain Associated With Soft Tissue Surgery in Dogs.
Friton G; Thompson C; Karadzovska D; King S; King JN
J Vet Intern Med; 2017 May; 31(3):832-841. PubMed ID: 28514527
[TBL] [Abstract][Full Text] [Related]
17. Safety of oral robenacoxib in the cat.
King JN; Hotz R; Reagan EL; Roth DR; Seewald W; Lees P
J Vet Pharmacol Ther; 2012 Jun; 35(3):290-300. PubMed ID: 21736587
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cardiovascular effects of intravenous robenacoxib in dogs.
Desevaux C; Marotte-Weyn AA; Champeroux P; King JN
J Vet Pharmacol Ther; 2017 Dec; 40(6):e62-e64. PubMed ID: 28457010
[TBL] [Abstract][Full Text] [Related]
19. Effect of meloxicam or robenacoxib administration timing on renal function and postoperative analgesia in cats undergoing ovariohysterectomy: A randomized, blinded, controlled clinical trial.
Krekis A; King JN; D'Arcy-Howard D; Stapleton N; Elliott J; Pelligand L
J Vet Pharmacol Ther; 2024 May; 47(3):175-186. PubMed ID: 38235901
[TBL] [Abstract][Full Text] [Related]
20. Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial.
Gruet P; Seewald W; King JN
BMC Vet Res; 2013 May; 9():92. PubMed ID: 23638669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
